SDIC Fund Management

Hipot is a technological innovation company dedicated to providing hydrogen fuel cell commercial vehicle transportation solutions.

Tianmei Times is a subsidiary of Techcomp ( Tianmei Group). Tianmei Times focusing on the fields of spectroscopy, chromatograph and mass spectrometry, life science laboratory equipment, etc.

Weikaier Pharmaceutical provides R&D of innovative drugs, transfer of generic drug technology, the production and sales of pharmaceuticals.

NASN Automotive Electronics Co., Ltd. is a manufacturer based in Shanghai, China, specializing in electronic chassis control products and autonomous driving technologies for the automotive market. The company offers a range of products, including the NBooster intelligent brake system, brushless electric steering EPS controller, and wire control systems. By focusing on research and development, production, and sales, NASN aims to provide advanced and comprehensive solutions that enhance vehicle safety and intelligence, catering to the growing demand for innovative automotive technologies in China.

Estun Codroid is a company that develops and applies generic intelligent robot technology. Estun Codroid focuses on promoting embodied intelligence technology and offers a variety of general intelligent human-machine collaboration robot products and application solutions to satisfy the needs of a broad market, including industry and services.

Beijing Shenzhou Puhui Technology is a high-tech company that specializes in AI big data, simulation training, and marine technology. Since its founding, it has focused on technology creation, technical consulting services, and the sale of associated products, all while advancing technological research and development and aiming for client success. Adhere to the combination of indigenous innovation and imported innovation, deliver world-class goods and expert services to the manufacturing, scientific research, and education sectors, aid users in enhancing their research and development capabilities and efficiency, and advance regional technological advancement.

Calterah specializes in the development of CMOS single-chip millimeter-wave radar sensors aimed at automotive applications. The company produces system-on-chip (SoC) products that integrate radar signal processing baseband technology, facilitating the design and implementation of mmWave radar sensors. These sensors find applications in various sectors, including both industrial and consumer markets, supporting technologies related to environmental sensing, autonomous obstacle avoidance, and radar imaging. Calterah's innovations contribute significantly to advancements in autonomous driving and related technologies.

Newcosemi Technology is a domestically owned integrated circuit design company specializing in the development and production of mid-to-high-end communication chips and high-definition display circuits. Utilizing its proprietary technology, the company focuses on electronic display applications, particularly for smartphones and televisions. This enables electronics manufacturers to incorporate advanced integrated circuit technology into their products, enhancing performance and display quality.

Mitro Biotech is a domestic molecular imaging medical research and development outsourcing enterprise that specializes in contract research services aimed at shortening the drug development cycle and minimizing the risk of failure. The company offers a comprehensive suite of solutions for both domestic and international pharmaceutical companies and research institutions. Its services encompass drug screening, biodistribution studies, pharmacokinetic research, and pharmacodynamic evaluation, thereby facilitating the efficient introduction of new drugs to the market. By providing these essential services, Mitro Biotech enables pharmaceutical developers to expedite the transition of their products from the research phase to clinical trials and eventual market launch.

Simcere Pharmaceutical Group is a prominent manufacturer and distributor of pharmaceuticals based in Nanjing, China, founded in 1995. The company has transitioned from a distributor to a leading player in China's pharmaceutical market, operating five GMP-certified manufacturing facilities and maintaining a strong workforce of over 4,000 employees. Simcere's product portfolio encompasses a wide range of medications targeting various therapeutic areas, including oncology, nervous system diseases, autoimmune disorders, and infections. Notable products include recombinant human endostatin injection for lung cancer, edaravone for acute cerebral infarction, and various formulations of amoxicillin for infections. The company also develops treatments for conditions such as arthritis, diarrhea, and cardiovascular diseases. Simcere has established strategic partnerships with organizations like Bristol-Myers Squibb and Jiangsu Alphamab Biopharmaceuticals to enhance its research and development capabilities.

News Dart is a manufacturer of precision planetary reducers and helps promote automation and intelligence transmission solutions.

Avistone Pharmaceuticals is a clinical-stage biotechnology company focused on precision oncology therapeutics.

Zhejiang Xinglaihe is a modern agricultural machinery manufacturing company. It is committed to the research and development, manufacturing, and sale of high-speed rice transplanters, tractors, diesel engines, and other agricultural machinery.

Tongxing Intelligence is a manufacturer of domestic self-contained automotive bus tool chains. They offer reliable products, complete services, and reasonable prices. It has provided independent, innovative solutions to engineering problems in automotive research and development, manufacturing, and industrial production for over two decades.

Bowang Pharmaceutical is an RNAi drug research and development platform focused on siRNA drug development.

Shunke Zhilian is a manufacturer of accessories for electric vehicles. It is a national high-tech enterprise integrating R&D, design, manufacturing, sales and after-sales service.

KHAT is a developer and producer of electronically controlled suspension for passenger vehicles.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

RFGene specializes in agricultural biotechnology, focusing on the research and development of products that enhance crop resilience, particularly against insects and pests. The company is involved in various aspects of biotechnology, including functional gene mining and the creation and screening of transformation bodies. RFGene also conducts safety evaluations for both domestic and international markets, aiming to cultivate a new generation of genetically modified crop varieties. Through its innovative approach, RFGene seeks to improve agricultural productivity and sustainability.

Adlai Nortye Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative cancer therapies and treatments for metabolic diseases. Founded in 2004 and based in Hangzhou, China, the company has established research and development and clinical operations in both China and the United States. Adlai Nortye has a diverse pipeline of over ten drug candidates, including several in various stages of clinical development, such as buparlisib (AN2025), palupiprant (AN0025), and AN4005, alongside preclinical candidates like AN8025, AN9025, and AN1025. The company emphasizes collaborations and internal discoveries to advance its strategic focus on oncology.

CanSemi is a semiconductor manufacturing company based in China, specializing in the production of microprocessors, power management chips, analog chips, and power discrete devices. The company operates as an integrated device manufacturer (IDM), focusing on addressing the domestic demand for chips in various sectors, including the Internet of Things, automotive electronics, industrial control, and 5G technology. By providing these essential components, CanSemi plays a significant role in supporting the growing technological landscape in China.

EpimAb Biotherapeutics is a biopharmaceutical company based in Shanghai, China, focused on the research and development of novel bispecific antibody therapeutics. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, the company creates bispecific molecules that possess antibody-like properties. This innovative approach aims to address the challenges associated with developing effective bi-specific antibodies, which are engineered from two different monoclonal antibodies to combine their therapeutic features into a single entity. These bispecific antibodies hold promise for treating various life-threatening conditions, particularly in immuno-oncology, by offering new therapeutic options. Despite the potential benefits of bi-specific antibodies, many candidates face hurdles in development due to issues related to their binding properties, pharmacokinetics, and production costs. EpimAb Biotherapeutics is positioned to contribute to the growing need for advanced bi-specific therapeutics in the pharmaceutical industry.

Zhejiang Leapmotor Technology Co., Ltd. is a prominent electric vehicle manufacturer based in Hangzhou, China. Established in 2015, the company focuses on the design, research and development, and production of intelligent electric vehicles. Leapmotor is committed to advancing technologies related to intelligent driving, motor electronic control, battery systems, and cloud computing for vehicle networking solutions. The company benefits from significant investment by Zhejiang Dahua Technology Co., Ltd., which provides robust financial support and expertise in technology research, development, and quality management. Leapmotor prioritizes technological innovation and industrial design, aiming to enhance process quality in its operations.

Zylox Medical Device Co., founded in 2012 in Hangzhou, is a specialized company focused on developing innovative medical devices for interventional procedures. Established by a team of experienced professionals with backgrounds in top-tier medical device manufacturers, Zylox offers a diverse range of products primarily aimed at peripheral vascular and neurovascular interventions. Its product line includes various devices such as PTA balloons, drug-coated PTA balloons, superficial femoral artery (SFA) stents, and the Thrombite Clot Retriever Device. Zylox is committed to improving patient outcomes by consistently enhancing its cutting-edge medical technologies and ensuring the highest quality standards.

Jianan Nongmu builds a new model of the agriculture and animal husbandry industry. The company is divided into three business units: digital supply chain financing, smart breeding, and smart logistics. Jianan Nongmu is dedicated to bringing back the agriculture and animal husbandry sectors of the economy through science and technology.

Beijing Mabworks Biotech, a gene engineering mAb company. Mabworks is working on ZMapp, an Ebola treatment developed by San Diego's MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech's Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.

Suzhou Ribo Life Science Co., Ltd. specializes in the development of nucleic acid drugs utilizing RNA interference (RNAi) technology, with a particular focus on treating liver diseases. Founded in 2007 and based in Kunshan, China, the company engages in various aspects of drug development, including drug discovery, siRNA design and screening, chemical modification, delivery technology, pharmacodynamics and pharmacokinetics studies, safety evaluation, and clinical trials. Suzhou Ribo Life Science offers siRNA therapeutics targeting conditions such as Hepatitis B, breast carcinoma, liver fibrosis, liver carcinoma, and HIV. The company has established a strategic partnership with Quark Pharmaceuticals, Inc. to enhance its research and development capabilities.

Peijia Medical Limited is a medical device company based in Suzhou, China, that specializes in the research, development, production, and sales of interventional procedural devices aimed at treating structural heart and neurovascular diseases. Founded in 2012, the company focuses on innovative products including various generations of transcatheter aortic valve replacement systems, as well as devices for transcatheter mitral and tricuspid valve replacements. In addition to its core offerings in heart valve therapies, Peijia Medical is advancing a range of ancillary products such as lithotripsy and balloon aortic valvuloplasty catheters, guidewires, and mitral repair devices. The company's neurointerventional product line includes stent retrievers, aspiration catheters, and detachable coils. With a commitment to high-quality medical technologies, Peijia Medical operates within a modern facility that supports its extensive R&D efforts in the growing interventional medical device market.

EpimAb Biotherapeutics is a biopharmaceutical company based in Shanghai, China, focused on the research and development of novel bispecific antibody therapeutics. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, the company creates bispecific molecules that possess antibody-like properties. This innovative approach aims to address the challenges associated with developing effective bi-specific antibodies, which are engineered from two different monoclonal antibodies to combine their therapeutic features into a single entity. These bispecific antibodies hold promise for treating various life-threatening conditions, particularly in immuno-oncology, by offering new therapeutic options. Despite the potential benefits of bi-specific antibodies, many candidates face hurdles in development due to issues related to their binding properties, pharmacokinetics, and production costs. EpimAb Biotherapeutics is positioned to contribute to the growing need for advanced bi-specific therapeutics in the pharmaceutical industry.

Qingtuanshe, founded in 2013, is a university part-time employment and flexible platform that is committed to more users. Qingtuanshe offers safer, richer, and more efficient part-time services to professional part-time recruitment services for more companies. As of January 2019, the registered users of Qingtuanshe is 6 million+, the number of registered companies is 100,000+, and the number of part-time applicants per day reached 240,000.

Zylox Medical Device Co., founded in 2012 in Hangzhou, is a specialized company focused on developing innovative medical devices for interventional procedures. Established by a team of experienced professionals with backgrounds in top-tier medical device manufacturers, Zylox offers a diverse range of products primarily aimed at peripheral vascular and neurovascular interventions. Its product line includes various devices such as PTA balloons, drug-coated PTA balloons, superficial femoral artery (SFA) stents, and the Thrombite Clot Retriever Device. Zylox is committed to improving patient outcomes by consistently enhancing its cutting-edge medical technologies and ensuring the highest quality standards.

FitSAMO is an orthopaedic surgical equipment supplier.

Banma Network Technologies is a global platform focused on providing innovative solutions for the automotive and transportation sectors. The company specializes in developing smart car operating systems and digital transportation services, aiming to enhance the connectivity between vehicles and cloud technology. By opening its AliOS in-car operating system to developers and car manufacturers, Banma seeks to facilitate the integration of connected car features, ultimately improving the overall user experience in smart mobility. Through its efforts, Banma Network is positioned to play a significant role in transforming the future of transportation.

Xinjinghe Laser Technology Development (Beijing) Co., Ltd. is a company that focuses on high-end manufacturing industries such as aerospace, navigation, and nuclear power. It specializes in complicated metal component customisation, product design and optimization, and software customization. Development and sales, technical advice and services, product remanufacturing and repair, 3D printing equipment manufacturing and sales of national high-tech businesses, is China's leading provider of metal additive/subtractive manufacturing technology comprehensive solutions.

RootCloud is a Beijing-based cloud computing platform founded in 2016 that specializes in Internet of Things (IoT) and industrial applications. The company connects industrial assets through various layers, including connection, platform, and application layers, to empower industries end-to-end. RootCloud targets machine manufacturers, equipment users, governmental regulatory agencies, and social organizations, offering services that encompass online machine management, smart manufacturing, research and development, and energy solutions. With over 10 years of experience, the company provides IoT and big data services globally, focusing on life-cycle management and digital transformation for large-scale manufacturing enterprises. By delivering software-as-a-service on the public cloud, RootCloud develops digital applications and solutions that enhance operational efficiency and improve product quality for its clients.

LP Pharmaceuticals (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.

Xinjinghe Laser Technology Development (Beijing) Co., Ltd. is a company that focuses on high-end manufacturing industries such as aerospace, navigation, and nuclear power. It specializes in complicated metal component customisation, product design and optimization, and software customization. Development and sales, technical advice and services, product remanufacturing and repair, 3D printing equipment manufacturing and sales of national high-tech businesses, is China's leading provider of metal additive/subtractive manufacturing technology comprehensive solutions.

Zensun (Shanghai) Sci & Tech Co., Ltd. is a biopharmaceutical company focusing on the development of innovative ‘first in class’ bio-therapeutic products for the treatment of serious and life-threatening unmet medical needs. They discover new medicines using novel disease specific targets and innovative technologies. The patented discoveries are then developed into therapies. With adherence to the tenet of “healing for life”, we hope to transform the lives of heart failure and cancer patients by providing them with drugs that treat their disease and not the symptoms. Zensun’s current pipeline covers cardiovascular disease treatment, anti-cancer drugs, and treatments for energy metabolism disorders.

Ninebot Inc. is a company that specializes in the design, development, manufacturing, distribution, and sale of short-distance personal transportation products. Founded in 2012 and headquartered in Beijing, China, Ninebot focuses on providing eco-friendly, electric, and self-balancing vehicles tailored for short-range commuting. The company serves a diverse customer base through a network of distributors and retail points both in China and internationally.

United Imaging Healthcare develops and manufactures medical equipment and solutions. Its solutions cover areas of diagnostics, radiotherapy, and healthcare information technology solutions. United Imaging Healthcare offers medical imaging products such as computed tomography, molecular imaging, magnetic resonance, and X-ray radiography products, radiotherapy equipment, and uCloud UIH Intelligent Medical Cloud, a medical cloud platform for medical resource sharing and mass diagnostic data mining. It also provides customer, technical support, dispatching, and training services. United Imaging Healthcare began operation in 2011, with its headquarters in Shanghai in China. It has locations in Concord, Cleveland, Houston, Wuhan, and Shenzhen.

CF PharmTech, Inc. is a specialty pharmaceutical company based in Suzhou, China, focused on the development and manufacturing of inhalation products for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. Founded in 2007, the company offers a range of products including metered dose inhalers, dry powder inhalers, nasal sprays, and nebulizers. In addition to its product offerings, CF PharmTech provides contract manufacturing organization (CMO) services and is actively involved in research and development in its specialized field. The company aims to provide high-quality and affordable medicines to enhance patient care and management of respiratory conditions, catering to a global market. Its headquarters are strategically located in the Caohu District, ensuring convenient transportation access to major cities like Shanghai and Beijing.

Novus Pharmaceuticals is a technology platform. The company provides solid oral preparations and human nutrition and health care products. The company's products dosage forms include sterile powder injection, sterile water injection, hard capsule, and tablet. They help people.

CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

Maxwell Technologies specializes in the development, manufacturing, and marketing of energy storage and power delivery solutions. Its products cater to various sectors, including automotive, heavy transportation, renewable energy, backup power, wireless communications, and industrial and consumer electronics. The company is known for producing ultra-high-voltage capacitors, as well as truck and generator starting capacitors, which are designed to deliver cost-effective, energy-efficient, and environmentally friendly performance. Maxwell Technologies aims to ensure failure-free operation throughout the lifespan of its products, even in the most demanding applications, and also develops radiation-hardened microelectronic components and systems for satellites and spacecraft.

Suzhou Ribo Life Science Co., Ltd. specializes in the development of nucleic acid drugs utilizing RNA interference (RNAi) technology, with a particular focus on treating liver diseases. Founded in 2007 and based in Kunshan, China, the company engages in various aspects of drug development, including drug discovery, siRNA design and screening, chemical modification, delivery technology, pharmacodynamics and pharmacokinetics studies, safety evaluation, and clinical trials. Suzhou Ribo Life Science offers siRNA therapeutics targeting conditions such as Hepatitis B, breast carcinoma, liver fibrosis, liver carcinoma, and HIV. The company has established a strategic partnership with Quark Pharmaceuticals, Inc. to enhance its research and development capabilities.

Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for cancer, hepatitis B virus (HBV), and age-related diseases. Founded in 2009 and headquartered in Suzhou, China, the company has established a diverse pipeline of drug candidates, including HQP1351, a BCR-ABL/KIT inhibitor targeting resistant mutations, and APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies. Additional candidates include APG-1252, aimed at restoring apoptosis in various solid tumors, and APG-115, which targets the MDM2-p53 interaction in solid tumors and lymphoma. Ascentage Pharma also develops APG-1387 for advanced solid tumors and chronic HBV infection, alongside other therapies for non-small-cell lung carcinoma and chronic lymphocytic leukemia. The company has entered into clinical collaborations to explore innovative treatment combinations, furthering its commitment to addressing challenging diseases in the oncology landscape.

Novogene Co., Ltd. is a prominent global provider of genomic services and solutions, specializing in next-generation sequencing (NGS) and bioinformatics. Founded in 2011 and headquartered in Beijing, China, the company operates with a large workforce and boasts the highest sequencing capacity worldwide. Novogene offers a wide range of genomic solutions, including human genome sequencing, cancer genomic profiling, and various applications for animals, plants, and microbes. Their advanced services also encompass clinical-grade whole exome sequencing and specialized diagnostic assays for cancer therapies. The company is recognized for its commitment to data quality and customer service, having produced over 1850 research papers in prestigious journals. Dr. Ruiqiang Li, the founder and a leading expert in genomics, has significantly contributed to the field through multiple patents and influential publications, fostering Novogene's reputation as a leader in the genomics sector.

Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacturing, and commercialization of monoclonal antibodies. The company focuses on therapeutic areas such as oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody approved for treating various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's pipeline includes several important candidates, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma, and IBI-303, an adalimumab biosimilar for autoimmune diseases. The company is also developing innovative therapies for conditions like hypercholesterolemia and various cancers. With a robust portfolio of commercialized products and ongoing strategic collaborations with major pharmaceutical companies, Innovent aims to expand its impact in the global biopharmaceutical landscape. Founded in 2011, Innovent is recognized as one of China's leading biotechnology firms.

GBase is a Chinese company that specializes in developing database software solutions. It serves a diverse range of industries, including finance, telecommunications, government, energy, transportation, and national defense. By providing domestic-developed software, GBase enables enterprises to leverage robust database technologies tailored to their specific needs. The company's focus on serving critical sectors underscores its commitment to enhancing data management and operational efficiency for its clients.

Duzhe is an application that provides a catalog of magazines. They have formed a range of journals. The company's contact mode is at its physical address.

Jiangsu Jland Biotech specializes in the development and production of Biollagen™, a non-animal-sourced collagen. The company is committed to becoming the largest supplier of this type of collagen globally. Utilizing advanced bioengineering technologies, including genetic recombination, microbial fermentation, and protein separation and purification, Jland Biotech designs and manufactures recombinant collagen. Their products cater to various industries, notably cosmetics and food, emphasizing the importance of sustainable and ethical sourcing in the collagen market.